



Deposited via The University of Leeds.

White Rose Research Online URL for this paper:

<https://eprints.whiterose.ac.uk/id/eprint/138520/>

Version: Accepted Version

---

**Article:**

Wittoek, R, Kroon, FPB, Kundakci, B et al. (2019) Report from the Hand Osteoarthritis Working Group at OMERACT 2018: Update on Core Instrument Set Development. *Journal of Rheumatology*, 46 (9). ISSN: 0315-162X

<https://doi.org/10.3899/jrheum.181003>

---

© Copyright 2019 The Journal of Rheumatology. This is an author produced version of a paper published in *Journal of Rheumatology*. Uploaded in accordance with the publisher's self-archiving policy. <https://doi.org/10.3899/jrheum.181003>.

**Reuse**

Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

**Takedown**

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk) including the URL of the record and the reason for the withdrawal request.

**Report from the Hand Osteoarthritis Working Group at  
OMERACT 2018: update on core instrument set development**

Journal:	<i>The Journal of Rheumatology</i>
Manuscript ID	2018-1003
Manuscript Type:	OMERACT
Date Submitted by the Author:	05-Sep-2018
Complete List of Authors:	<p>Wittoek, Ruth; University Hospital Gent, Rheumatology; University Gent            Kroon, Féline; Leids Universitair Medisch Centrum, Rheumatology            Kundakci, Burak; University of Nottingham, Division of Academic            Rheumatology            Abhishek, Abhishek; University of Nottingham, Division of Academic            Rheumatology; National Institute for Health Research, Nottingham            Biomedical Research Centre            Haugen, Ida; Diakonhjemmet Sykehus AS, Rheumatology            Berenbaum, Francis; Sorbonne Universités, UPMC Univ Paris 06, INSERM;            Hôpital Saint-Antoine, AP-HP, DHU i2B, Department of Rheumatology            Conaghan, Philip; University of Leeds, Leeds Institute of Rheumatic and            Musculoskeletal Medicine            Ishimori, Mariko; Cedars-Sinai Medical Center, Division of Rheumatology            van der Heijde, Désirée; Leiden University Medical Center, Rheumatology            Kloppenburg, Margreet; Leiden University Medical Center, Department of            Rheumatology; Leiden University Medical Center, Department of Clinical            Epidemiology</p>
Keywords:	Osteoarthritis, Hand, Outcomes, OMERACT

## **Report from the Hand Osteoarthritis Working Group at OMERACT 2018: update on core instrument set development**

*Ruth Wittoek<sup>1</sup>, Féline P.B. Kroon<sup>2</sup>, Burak Kundakci<sup>3</sup>, Abhishek Abhishek<sup>3,4</sup>, Ida K. Haugen<sup>5</sup>, Francis Berenbaum<sup>6</sup>, Philip G. Conaghan<sup>7</sup>, Mariko L. Ishimori<sup>8</sup>, Désirée van der Heijde<sup>2</sup>, Margreet Kloppenburg<sup>2,9</sup>*

<sup>1</sup>Department of Rheumatology, University Hospital Ghent, Ghent University, Ghent, Belgium

<sup>2</sup>Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands

<sup>3</sup>Division of Academic Rheumatology, University of Nottingham, Nottingham, United Kingdom

<sup>4</sup>National Institute for Health Research, Nottingham Biomedical Research Centre, Nottingham, United Kingdom

<sup>5</sup>Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway

<sup>6</sup>Department of Rheumatology, Sorbonne Université, INSERM, Saint-Antoine hospital AP-HP, DHU i2B, Paris, France

<sup>7</sup>Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and National Institute for Health Research, Leeds Biomedical Research Centre, Leeds, United Kingdom

<sup>8</sup>Department of Medicine, Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, California, USA

<sup>9</sup>Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands

### **Authors list:**

Ruth Wittoek, MD, PhD, ORCID id: 0000-0002-6367-9466

Féline P.B. Kroon, MD, ORCID id: 0000-0002-8940-0582

Burak Kundakci, PT, MSc, ORCID id: 0000-0002-3507-1111

Abhishek Abhishek, MD, MRCP, PhD, ORCID id : 0000-0003-0121-4919

Ida K. Haugen, MD, PhD, ORCID id : 0000-0001-7810-2216

Francis Berenbaum, MD, PhD, ORCID id: 0000-0001-8252-7815

Philip G Conaghan MBBS, PhD, FRACP, FRCP, ORCID id: 0000-0002-3478-5665

Mariko L. Ishimori, MD, ORCID id: 0000-0002-0421-8854

Désirée van der Heijde, MD, PhD, ORCID id: 0000-0002-5781-158X

Margreet Kloppenburg, MD, PhD, ORCID id: 0000-0002-9294-2307

**Keywords:** OMERACT, hand osteoarthritis, outcome measurement

**Word count:** 1378

**Funding:** none

**Conflict of interest:** RW, FK, BK, AA, IKH, FB, PGC, MLI, DvdH, MK: nothing to declare

**Short running title:** OMERACT 2018 Hand OA

**Corresponding author:** M. Kloppenburg, Department of Rheumatology, Leiden University Medical Center, PO Box 9600, 2300 RC, Leiden, Netherlands. E-mail address: [g.kloppenburg@lumc.nl](mailto:g.kloppenburg@lumc.nl)

Telephone number: +31 71 5263598.

For Peer Review

## **ABSTRACT**

**Objective.** Evaluate hand osteoarthritis tools for core instrument set development.

**Methods.** For OMERACT2018, a systematic literature review and advances in instrument validation were presented.

**Results.** Visual analogue and numeric rating scales were considered valuable for pain and patient global assessment, despite heterogeneous phrasing and missing psychometric evidence for some aspects. Modified Intermittent and Constant Osteoarthritis Pain was lacking evidence. Michigan Hand Outcomes Questionnaire had advantages above other pain/function questionnaires. Hand Mobility in Scleroderma was valid, although responsiveness was questioned. Potential joint activity instruments were evaluated.

**Conclusion.** The core instrument set development is progressing, and a research agenda was also developed.

For Peer Review

## **INTRODUCTION**

Hand osteoarthritis (OA) is a highly prevalent disorder, causing a considerable burden of disease(1). Simultaneous involvement of multiple hand joints and presence of different subsets (e.g., nodal, thumb base and erosive OA) make it difficult to study. To advance our understanding, high-quality studies with optimal outcome measurement are essential.

The Outcome Measures in Rheumatology (OMERACT) Hand OA Working Group (WG), assembled in 2010, endorsed a core domain set for clinical trials of symptom and structure modification and observational studies at OMERACT 2014(2), which was included in the Osteoarthritis Research Society International (OARSI) recommendations for design and conduct of clinical trials in hand OA(3). The core domain set includes six domains for all settings (pain, physical function, patient global assessment (PGA), health-related quality of life (HRQoL), joint activity, and hand strength), and two additional domains for trials of structure modification and observational studies (hand mobility and structural damage). HRQoL and hand mobility are not mandatory domains.

A preliminary core instrument set was also proposed including visual analogue (VAS) or numeric rating scale (NRS) pain, Functional Index for Hand OA (FIHOA), tender joint count and pinch/grip strength(2). Subsequent goals of the WG were to (1) evaluate relevant instruments according to OMERACT Handbook (4), and (2) update the research agenda on final core instrument set selection(5). Progress was discussed at OMERACT 2018.

## **METHODS**

### **Review of instruments measuring pain and patient global assessment (PGA)**

A systematic literature review (SLR) was performed (RW, BK, AA) including studies reporting on hand pain and PGA measured on VAS or NRS in patients with hand OA. A previous SLR on measurement properties of pain and function instruments in hand OA until January 2014 was used as a basis(6). Relevant manuscripts from that SLR were extracted. Additionally, medical literature databases (Pubmed, Embase, Web of Science, COCHRANE, CINAHL, Academic Search Premier, ScienceDirect) were searched from January 2014 to January 2018 applying similar methodology (see supplementary file). Psychometric features of the scales such as reliability, responsiveness, construct validity and clinical trial discrimination were extracted and evaluated according to OMERACT Handbook (4). These features were discussed at OMERACT 2018. Special attention was given to the phrasing and other details of the VAS/NRS question.

Construct validity of the modified Intermittent and Constant OA Pain (ICOAP) (IKH,(7-9)) was studied in the Nor-Hand study to investigate whether constant and intermittent pain were separate constructs in hand OA.

### **Investigation of other potential core instruments**

Recent work was conducted by WG members on the relevant validity and psychometric properties of other tools: (1) Properties of the Michigan Hand Outcomes Questionnaire (MHQ) (FK,(10, 11)) were compared to more commonly used hand OA questionnaires, specifically Australian/Canadian Hand OA Index (AUSCAN) and FIHOA(12, 13); (2) Performance of Hand Mobility in Scleroderma (HAMIS) and its responsiveness was compared to other mobility instruments (FK,(14)); (3) Assessment of tender joint count to measure joint activity (FK, (15, 16)).

### **Research agenda**

Guided by discussions at OMERACT 2018, a research agenda was developed.

## **RESULTS**

### **Domain pain and PGA: progress in instrument validation**

From the previous SLR, 32 relevant manuscript were selected providing data on VAS/NRS pain and/or PGA(6). Since January 2014, 18 relevant manuscripts were published and could be added (S1-S50, see reference list in supplements). Details of all included manuscripts can be found in supplementary table 1. Summary results of the search (supplementary figure 1) and psychometric features of both scales within these domains were discussed by the WG (table 1). VAS range 0-100 mm was the most studied scale (in 26/46 studies for pain and 10/15 studies for PGA). No study reported test-retest reliability data on the use of either scale in these domains. For pain, good construct validity of VAS was shown(S3, S24, S50), while only limited data were available for NRS(S41). Twenty-three(S1, S2, S4, S6-S13, S15-S18, S21, S22, S26, S37, S38, S42, S46) and eight studies(S15, S25, S28, S33, S34, S41, S45, S47) showed evidence for responsiveness of VAS and NRS, and 13(S7-S12, S17, S21, S22, S26, S37, S38, S46) and six studies(S14, S28, S33, S34, S41, S47) for clinical trial discrimination.

For PGA, construct validity was not studied. Evidence to support responsiveness for VAS was available in ten(S3, S6, S12, S13, S15, S18, S22, S29, S38, S40), and three studies for NRS(S14, S28, S45) . The capacity to discriminate in clinical trials was shown for VAS PGA in agreement with the primary outcome in five studies(S12, S22, S29, S38, S40), while for NRS only one study supported this(S28).

Strikingly, phrasing of the question accompanying VAS/NRS in both domains was very heterogeneous, and details were often not reported. For pain, substantial variety existed in which aspect(s) of pain were assessed (e.g., pain at rest or upon exertion, average or worst pain), location and joint(s) referred to (e.g.,target joints, dominant hand, both hands) and time of recall (undefined or ranging from current to 2 weeks) (supplementary table 2). Likewise, for PGA, time of recall was undefined in most studies (3/15 studies did specify (all 48 hours)) (supplementary table 3). After

presentation of these findings at OMERACT 2018, the WG proposed that clear standardized phrasing accompanying these instruments should be defined for pain and PGA. It was proposed that PGA should assess the impact of the disease on the patient's general well-being. Review of results of previously held focus groups was suggested to explore what is most relevant to patients(17).

Results of the validation study of the modified ICOAP were discussed at OMERACT 2018. Detailed results are presented elsewhere(9). In short, in hand OA patients, constant and intermittent pain largely overlapped and were not separate constructs, in contrast to the situation in knee and hip OA (7, 8). The existence of separate constructs in hand OA seemed clinically plausible, but might be influenced by hand OA location (finger versus thumb base) and involvement of multiple hand joints at different disease stages. It was suggested to seek more patient input, since the development of ICOAP was based on focus group discussions with patients with knee and hip OA, but not hand OA. However, previous focus groups of hand OA patients have already identified a range of pain concepts, such as fluctuating pain and psychological consequences of pain, which are not represented in the commonly used instruments to assess hand OA (17).

Based on the available evidence, it was concluded that VAS and NRS are most likely the best instruments to measure pain and PGA. However, evidence about some essential psychometric properties is missing, in particular regarding reliability, construct validity for NRS pain/PGA, and clinical trial discrimination for NRS PGA.

#### **Evaluation of other potential core instruments and research agenda**

The results of comparison of MHQ with AUSCAN and FIHOA for measuring domains pain and function were discussed in light of OMERACT Filter 2.1(4) (table 2 and (11)). While displaying similar measurement properties, important advantages of MHQ above other instruments were that it can overcome issues of copyright (AUSCAN) and outdated questions (FIHOA). The possibility to propose more than one instrument for a core domain, with the accompanying risk of jeopardising standardisation, was discussed.

Assessment of performance of HAMIS in comparison to other mobility instruments was published previously(14). Though HAMIS appeared the most useful to measure hand mobility compared to other instruments, the WG debated that responsiveness data are weak. Over a two-year period, limited change over time was observed(14), either indicating that the domain itself does not change, or that the instrument cannot detect this change.

Progress in instrument development for joint activity is published in conference abstracts(15, 16). Lack of a well-accepted definition hampers instrument development for this domain. Potential instruments include inflammation on imaging (ultrasound, magnetic resonance imaging), pain upon palpation, self-reported painful joint count, soft tissue swelling, and pain while gripping. In the WG

discussion it was suggested that some instruments complement each other, and a combination may be useful. Prediction of radiological progression was proposed as an anchor to assess suitable instruments.

Following discussion of these results, a research agenda was developed to guide future research (table 3).

## **DISCUSSION**

Results of progress of development of a core instrument set for hand OA through investigation of the psychometric properties of candidate instruments according to OMERACT Handbook (4), assessing construct validity, reliability, responsiveness and clinical trial discrimination, were presented, discussed, and serve as the basis of an updated research agenda.

## **Acknowledgements**

PGC is supported in part by the UK NIHR Leeds Biomedical Research Centre. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health.

## REFERENCES

1. Kloppenburg M, Kwok WY. Hand osteoarthritis--a heterogeneous disorder. *Nat Rev Rheumatol* 2011;8:22-31
2. Kloppenburg M, Bøyesen P, Visser A, Haugen I, Boers M, Boonen A, et al. Report from the OMERACT Hand Osteoarthritis Working Group: Set of Core Domains and Preliminary Set of Instruments for Use in Clinical Trials and Observational Studies. *J Rheumatol* 2015;42:2190-7
3. Kloppenburg M, Maheu E, Kraus VB, Cicuttini F, Doherty M, Dreiser RL, et al. OARSI Clinical Trials Recommendations: Design and conduct of clinical trials for hand osteoarthritis. *Osteoarthritis Cartilage* 2015;23:772-86
4. Boers M, Kirwan JR, Tugwell P, Beaton D, Bingham CO III, Conaghan PG, et al. The OMERACT Handbook. [Internet. Accessed May 17, 2017] Available from: <https://omeract.org/resources>
5. Boers M, Kirwan JR, Wells G, Beaton D, Gossec L, d'Agostino MA, et al. Developing core outcome measurement sets for clinical trials: OMERACT filter 2.0. *J Clin Epidemiol* 2014;67:745-53.
6. Visser AW, Boyesen P, Haugen IK, Schoones JW, van der Heijde DM, Rosendaal FR, et al. Instruments Measuring Pain, Physical Function, or Patient's Global Assessment in Hand Osteoarthritis: A Systematic Literature Search. *J Rheumatol* 2015;42:2118-34
7. Hawker GA, Davis AM, French MR, Cibere J, Jordan JM, March L, et al. Development and preliminary psychometric testing of a new OA pain measure – an OARSI/OMERACT initiative. *Osteoarthritis Cartilage* 2008;16:409-14
8. Hawker GA, Stewart L, French MR, Cibere J, Jordan JM, March L, et al. Understanding the pain experience in hip and knee osteoarthritis - an OARSI/OMERACT initiative. *Osteoarthritis Cartilage* 2008;16:415-22
9. Gløersen M, Pettersen PS, Tore KK, Haugen IK. Validation of the Intermittent and Constant Osteoarthritis Pain (ICOAP) questionnaire in patients with hand osteoarthritis. Results from the Nor-Hand study. *J Rheumatol* 2018 submitted.
10. Chung KC, Pillsbury MS, Walters MR, Hayward RA. Reliability and validity testing of the Michigan Hand Outcomes Questionnaire. *J Hand Surg Am* 1998;23:575-87
11. Kroon FPB, Boersma A, Boonen A, van Beest S, Damman W, van der Heijde D, et al. Performance of the Michigan Hand Outcomes Questionnaire in hand osteoarthritis. *Osteoarthritis Cartilage* 2018 Aug 9 [in press]
12. Bellamy N, Campbell J, Haraoui B, Buchbinder R, Hobby K, Roth JH, et al. Dimensionality and clinical importance of pain and disability in hand osteoarthritis: Development of the Australian/Canadian (AUSCAN) Osteoarthritis Hand Index. *Osteoarthritis Cartilage* 2002;10:855-62
13. Dreiser R, Maheu E, Guillou G, Caspard H, Grouin J. Validation of an algofunctional index for osteoarthritis of the hand. *Rev Rhum Engl Ed* 1995;62:43S-53S
14. Kroon FPB, Damman W, Liu R, Bijsterbosch J, Meulenbelt I, van der Heijde D, et al. Validity, reliability, responsiveness and feasibility of four hand mobility measures in hand osteoarthritis. *Rheumatology (Oxford)* 2018;57:525-32
15. Damman W, Liu R, Kortekaas M, Rosendaal F, van der Heijde D, Kloppenburg M. Construct validity of the Doyle Index in the outcome domain of joint activity in hand osteoarthritis patients. *Osteoarthritis Cartilage* 2016;24:S434
16. Kroon FPB, van der Plas JL, van Beest S, Damman W, Kloppenburg M. Investigation of self-reported painful joint count as an outcome measure in hand osteoarthritis. *Osteoarthritis Cartilage* 2018;26:S213-S4
17. Stamm T, van der Giesen F, Thorstensson C, Steen E, Birrell F, Bauernfeind B, et al. Patient perspective of hand osteoarthritis in relation to concepts covered by instruments measuring functioning: a qualitative European multicentre study. *Ann Rheum Dis* 2009;68:1453-60

## TABLES AND FIGURES

**Table 1.** Metric properties of VAS and NRS measuring pain and patient global assessment (PGA): construct validity, reliability, longitudinal construct validity (responsiveness) and clinical trial discrimination.

**Table 2.** Comparison of properties of Michigan Hand Outcomes Questionnaire (MHQ), Australian/Canadian Hand Osteoarthritis Index (AUSCAN), and Functional Index for Hand Osteoarthritis (FIHOA).

**Table 3.** Future research agenda to progress core instrument set selection for hand OA

For Peer Review

Table 1. Metric properties of VAS and NRS measuring pain and patient global assessment (PGA): construct validity, reliability, longitudinal construct validity (responsiveness) and clinical trial discrimination.

Domain	Scale	Construct validity	Reliability	Longitudinal construct validity (responsiveness)			Clinical trial discrimination			
		Studies showing significant correlation with:	No of studies	No of studies showing change	No of studies showing no change, in disagreement with other outcomes	Percentage of studies that detected change	No of studies showing discrimination between arms in agreement with primary outcome	No of studies not showing discrimination between arms in agreement with primary outcome	No of studies showing discrimination between arms in disagreement with primary outcome	No of studies not showing discrimination between arms in disagreement with primary outcome
Pain	VAS	AUSCAN pain: $r = 0.77 - 0.81$ (S3, S24, S50)	0	23 (S1, S2, S4, S6-S13, S15-S18, S21, S22, S26, S37, S38, S42, S46) <sup>#</sup>	3 (S31, S39, S44)	88	13 (S7-S12, S17, S21, S22, S26, S37, S38, S46)	6 (S1, S5, S6, S23, S32, S44)	2 (S13, S42)	7 (S15, S19, S30, S39, S43, S48, S49)
	NRS	AUSCAN pain: $R^2 = 0.606$ (S41) AUSCAN function: $R^2 = 0.471$ (S41)	0	8 (S15, S25, S28, S33, S34, S41, S45, S47)	0	100	6 (S14, S28, S33, S34, S41, S47)	0	1 (S16)	1 (S25)
PGA	VAS	0	0	10 (S3, S6, S12, S13, S15, S18, S22, S29, S38, S40) <sup>#</sup>	0	100	5 (S12, S22, S29, S38, S40)	2 (S6, S40)	1 (S15)	0
	NRS	0	0	3 (S14, S28, S45)	0	100	1 [S28]	0	0	1 (S14)

<sup>#</sup>Saviola et al., 2017 (S38): no hard data shown, only described in full text; No: number; VAS: visual analogue scale; NRS: numeric rating scale; AUSCAN: Australian/Canadian Hand OA Index; r: coefficient of correlation;  $R^2$ : correlation. S(number): refers to the reference in the supplementary reference list.

Table 2. Comparison of properties of Michigan Hand Outcomes Questionnaire (MHQ), Australian/Canadian Hand Osteoarthritis Index (AUSCAN), and Functional Index for Hand Osteoarthritis (FIHOA).

	MHQ(10)	AUSCAN(12)	FIHOA(13)
<b>Domain: Pain</b>			
Number of items	5	5	-
Floor and ceiling effects*	No (1.8% with lowest score, 0% with highest score)	No (1.8% with lowest score, 1.3% with highest score)	-
Aspect of pain assessed	Frequency of experiencing pain in several situations (in general, during sleep or ADL) and whether it affects the respondent's happiness.	Pain severity during rest and several tasks (lifting, squeezing, turning, gripping)	-
Specific other comments	No	No	-
<b>Domain: Function</b>			
Number of items	Overall hand function scale: 10 ADL scale: 17	9	10
Floor and ceiling effects*	No (subscales overall hand function/ADL: 0%/0% with lowest score, 1.3%/3.1% with highest score)	No (1.8% with lowest score, 0.3% with highest score)	No (4.2% with lowest score, 0% with highest score)
Aspect of function assessed	Overall hand function scale: General questions of hand function, movement, strength and sensation. ADL scale: Ability to perform certain tasks (turning doorknob, picking up coin, holding glass of water, turning key in lock, holding heavy object with one hand, opening jar, buttoning shirt, using cutlery, carrying large and heavy objects, washing dishes, washing hair, tying shoelaces or knots); 4/12 grip strength tasks, 3/12 fine motor skills tasks.	Ability to perform certain tasks (turning doorknobs, holding heavy object with one hand, buttoning shirt, using cutlery, carrying large and heavy objects, turning taps, fastening jewelry, wringing cloth); 4/9 grip strength tasks, 2/9 fine motor skills tasks.	Ability to perform certain tasks (turning key in lock, holding heavy objects, buttoning shirt, using cutlery, tying shoelaces or knots, cutting with scissors, clenching fist, sewing (women) / using screwdriver (men), writing for a long time, accepting a handshake); 1/10 grip strength tasks, 4/10 fine motor skills tasks.
Specific other comments	Separate assessment of left and right hand.	No	Some items may be culturally challenging (accepting a handshake), or outdated (writing for more than 10 minutes; women sew and men use a screwdriver)
<b>General aspects</b>			

Recall period	1 week	48 hours	Not specified
Other available subscales (domain)	Work performance (N/A) Aesthetics (Structural damage) Satisfaction (N/A)	Stiffness (N/A)	N/A
Total number of items	58	15	10
Method of scoring	Includes normalizing to 0-100 scale, presented in user manual	Dependent on version used (Likert scale, VAS), presented in user manual	Simple addition of scores, user guide available online
Costs	Freely available for academic or non-profit institutions, permission needed before use (online application form)	Copyrighted, payment of fee and permission needed before use	No
Available in multiple languages	Yes	Yes	Yes
Interpretability comments	Pain scale has to be interpreted in opposite direction compared to other subscales	No	No

ADL, activities of daily living; N/A, not available; VAS, visual analogue scale.

\*Data reviewed in HOSTAS cohort (N=383), LUMC, Leiden, The Netherlands

Table 3. Future research agenda to progress core instrument set selection for hand OA

<ul style="list-style-type: none"> <li>• Definition of standardized phrasing for VAS and NRS pain and PGA</li> </ul>
<ul style="list-style-type: none"> <li>• Assessment of test-retest reliability of VAS and NRS pain and PGA</li> </ul>
<ul style="list-style-type: none"> <li>• Investigation of construct validity for NRS pain and PGA, and discriminative capacity in clinical trials for NRS PGA</li> </ul>
<ul style="list-style-type: none"> <li>• Investigation of validity of combinations of instruments to assess joint activity, including e.g., tender joints, self-reported painful joints, swollen joints, pain while gripping, and inflammatory signs on imaging</li> </ul>
<ul style="list-style-type: none"> <li>• Assessment of reliability of soft tissue joint swelling in hand OA</li> </ul>
<ul style="list-style-type: none"> <li>• Investigation of psychometric properties of grip and pinch strength to measure core domain hand strength</li> </ul>
<ul style="list-style-type: none"> <li>• Review of available instruments to assess health-related quality of life in hand OA, and development of a disease-specific instrument</li> </ul>
<ul style="list-style-type: none"> <li>• Investigation of the metric properties of ultrasound and magnetic resonance imaging</li> </ul>
<ul style="list-style-type: none"> <li>• Investigation of the value of computer tomography</li> </ul>

VAS: visual analogue scale; NRS: numeric rating scale; PGA: patient global assessment; OA: osteoarthritis

**SUPPLEMENTARY DATA****METHODS:****Systematic literature review (SLR) of VAS/NRS pain and patient global assessment (PGA)**

Studies that did not include VAS or NRS to measure pain or PGA were excluded as well as studies only including thumb base OA. Relevant manuscripts were also extracted from the SLR by Visser *et al.* for the purpose of this work. All retrieved titles and selected abstracts were reviewed by one reviewer (BK). A random sample of 100 titles was reviewed by a second reader (RW) with perfect agreement. Data extraction from all selected full-text manuscripts was done by one reviewer (RW). Psychometric features of the scales such as reliability, responsiveness, construct validity and clinical trial discrimination were extracted. Special attention was given to the explicit phrasing and other details of the accompanying question. Because of the heterogeneity of the studies with respect to the instruments, only descriptive analyses were performed.

**FIGURE LEGENDS**

Figure 1. Overview of manuscript selection for NRS/VAS pain/PGA

OA: osteoarthritis; VAS: visual analogue scale; NRS: numeric rating scale; PGA: patient global assessment

For Peer Review

Table 1: Details of included studies

Table 2: Details of phrasing of question accompanying VAS or NRS pain

Table 3: Details of phrasing of question accompanying VAS or NRS PGA

For Peer Review

## Supplement references:

1. Aitken D, Laslett LL, Pan F, Haugen IK, Otahal P, Bellamy N, et al. A randomised double-blind placebo-controlled crossover trial of HUMira (adalimumab) for erosive hand Osteoarthritis - the HUMOR trial. *Osteoarthritis Cartilage*. 2018 Mar 2 [in press].
2. Baltzer AW, Ostapczuk MS, Stosch D. Positive effects of low level laser therapy (LLLT) on Bouchard's and Heberden's osteoarthritis. *Lasers Surg Med*. 2016; 48:498-504.
3. Barthel HR, Peniston JH, Clark MB, Gold MS, Altman RD. Correlation of pain relief with physical function in hand osteoarthritis: randomized controlled trial post hoc analysis. *Arthritis Res Ther*. 2010;12:R7.
4. Bjurehed L, Brodin N, Nordenskiöld U, Bjork M. Improved Hand Function, Self-Rated Health and Decreased Activity Limitations - results after a two month hand osteoarthritis group intervention. *Arthritis Care Res (Hoboken)*. 2017;70:1039-1045.
5. Brosseau L, Wells G, Marchand S, Gaboury I, Stokes B, Morin M, et al. Randomized controlled trial on low level laser therapy (LLLT) in the treatment of osteoarthritis (OA) of the hand. *Laser Surg Med*. 2005; 36:210-219.
6. Chevalier X, Ravaut P, Maheu E, Baron G, Riolland A, Vergnaud P, et al. Adalimumab in patients with hand osteoarthritis refractory to analgesics and NSAIDs: a randomised, multicentre, double-blind, placebo-controlled trial. *Ann Rheum Dis*. 2015;74:1697-1705.
7. Dilek B, Gozum M, Sahin E, Baydar M, Ergor G, El O, et al. Efficacy of Paraffin Bath Therapy in Hand Osteoarthritis: A Single-Blinded Randomized Controlled Trial. *Arch Phys Med Rehab*. 2013; 94:642-649.
8. Dreiser RL, Gersberg M, Thomas F, Courcier S. Ibuprofen 800 Mg for the Treatment of Osteoarthritis of the Interphalangeal Joints of the Hand or Trapeziometacarpal Joint. *Rev Rhum*. 1993;60:836-841.
9. Fioravanti A, Tenti S, Giannitti C, Fortunati NA, Galeazzi M. Short- and long-term effects of mud-bath treatment on hand osteoarthritis: a randomized clinical trial. *Int J Biometeorol*. 2014; 58:79-86.
10. Gabay C, Medinger-Sadowski C, Gascon D, Kolo F, Finckh A. Symptomatic Effects of Chondroitin 4 and Chondroitin 6 Sulfate on Hand Osteoarthritis A Randomized, Double-Blind, Placebo-Controlled Clinical Trial at a Single Center. *Arthritis Rheum*. 2011; 63:3383-3391.
11. Garfinkel MS, Schumacher HR, Husain A, Levy M, Reshetar RA. Evaluation of a Yoga Based Regimen for Treatment of Osteoarthritis of the Hands. *J Rheumat*. 1994;21:2341-2343.
12. Grifka JK, Zacher J, Brown JP, Seriola B, Lee A, Moore A, et al. Efficacy and tolerability of lumiracoxib versus placebo in patients with osteoarthritis of the hand. *Clin Exp Rheumatol*. 2004;22:589-596.
13. Gyarmati N, Kulisch A, Nemeth A, Bergmann A, Horvath J, Mando Z, et al. Evaluation of the Effect of Heviz Mud in Patients with Hand Osteoarthritis: A Randomized, Controlled, Single-Blind Follow-Up Study. *Isr Med Assoc J*. 2017;19:177-182.
14. Hennig T, Haehre L, Hornburg VT, Mowinkel P, Norli ES, Kjekken I. Effect of home-based hand exercises in women with hand osteoarthritis: a randomised controlled trial. *Ann Rheum Dis*. 2015;74:1501-1508.
15. Horváth K, Kulisch A, Németh A, Bender T. Evaluation of the effect of balneotherapy in patients with osteoarthritis of the hands: a randomized controlled single-blind follow-up study. *Clinical Rehabilitation*. 2011;26:431-441.
16. Kanat E, Alp A, Yurtkuran M. Magnetotherapy in hand osteoarthritis: A pilot trial. *Complement Ther Med*. 2013;21:603-608.
17. Kasapoglu MA, Altan L, Erosuz R, OkmenMetin B. The Efficacy of Peloid Therapy in Management of Hand Osteoarthritis. *Ann Rheum Dis*. 2017;76:974-974.

18. Keen HI, Wakefield RJ, Hensor EMA, Emery P, Conaghan PG. Response of symptoms and synovitis to intra-muscular methylprednisolone in osteoarthritis of the hand: an ultrasonographic study. *Rheumatology (Oxford)*. 2010;49:1093-1100.
19. Kjekken I, Darre S, Smedslund G, Hagen KB, Nossum R. Effect of assistive technology in hand osteoarthritis: a randomised controlled trial. *Ann Rheum Dis*. 2011;70:1447-1452.
20. Kortekaas MC, Kwok WY, Reijnierse M, Huizinga TW, Kloppenburg M. Follow-up study of inflammatory ultrasound features in hand osteoarthritis over a period of 3 months: variable as well as constant. *Osteoarthritis Cartilage*. 2014;22:40-43.
21. Kovacs C, Pecze M, Tihanyi A, Kovacs L, Balogh S, Bender T. The effect of sulphurous water in patients with osteoarthritis of hand. Double-blind, randomized, controlled follow-up study. *Clin Rheumatol*. 2012;31:1437-1442.
22. Kvien TK, Fjeld E, Slatkowsky-Christensen B, Nichols M, Zhang Y, Proven A, et al. Efficacy and safety of a novel synergistic drug candidate, CRx-102, in hand osteoarthritis. *Ann Rheum Dis*. 2008;67:942-948.
23. Lee W, Ruijgrok L, Boxma-de Klerk B, Kok MR, Kloppenburg M, Gerards A, et al. Efficacy of hydroxychloroquine in hand osteoarthritis: a randomized, double blind, placebo-controlled trial. *Arthritis Care Res (Hoboken)*. 2018;70:1320-1325.
24. Moe RH, Garratt A, Slatkowsky-Christensen B, Maheu E, Mowinckel P, Kvien TK, et al. Concurrent evaluation of data quality, reliability and validity of the Australian/Canadian Osteoarthritis Hand Index and the Functional Index for Hand Osteoarthritis. *Rheumatology (Oxford)*. 2010;49:2327-2336.
25. Moe RH, Grotle M, Kjekken I, Olsen IC, Mowinckel P, Haavardsholm EA, et al. Effectiveness of an Integrated Multidisciplinary Osteoarthritis Outpatient Program versus Outpatient Clinic as Usual: A Randomized Controlled Trial. *J Rheumatol*. 2016;43:411-418.
26. Myrner JW, Johnson AW, Mitchell UH, Measom GJ, Fellingham GW. Topical analgesic added to paraffin enhances paraffin bath treatment of individuals with hand osteoarthritis. *Disabil Rehabil*. 2011;33:467-474.
27. Neuprez A, Bruyere O, Maheu E, Dardenne N, Burlet N, D'Hooghe P, et al. Aesthetic discomfort in hand osteoarthritis: results from the Llege Hand Osteoarthritis Cohort (LIHOC). *Arthritis Res Ther*. 2015;17:346.
28. Osteras N, Hagen KB, Grotle M, Sand-Svartrud AL, Mowinckel P, Kjekken I. Limited effects of exercises in people with hand osteoarthritis: results from a randomized controlled trial. *Osteoarthritis Cartilage*. 2014;22:1224-1233.
29. Park JK, Shin K, Kang EH, Ha YJ, Lee YJ, Lee KH, et al. Efficacy and Tolerability of GCSB-5 for Hand Osteoarthritis: A Randomized, Controlled Trial. *Clin Ther*. 2016;38:1858-1868.
30. Pastinen O, Forsskahl B, Marklund M. Local Glycosaminoglycan Polysulfate Injection Therapy in Osteo-Arthritis of the Hand - a Placebo-Controlled Clinical-Study. *Scan J Rheumatol*. 1988;17:197-202.
31. Poiraudreau S, Chevalier X, Conrozier T, Flippo RM, Liote F, Noel E, et al. Reliability, validity, and sensitivity to change of the Cochin hand functional disability scale in hand osteoarthritis. *Osteoarthritis Cartilage*. 2001;9:570-577.
32. Romero-Cerecero O, Meckes-Fischer M, Zamilpa A, Jimenez-Ferrer JE, Nicasio-Torres P, Perez-Garcia D, et al. Clinical trial for evaluating the effectiveness and tolerability of topical *Sphaeralcea angustifolia* treatment in hand osteoarthritis. *J Ethnopharmacol*. 2013;147:467-473.
33. Rothacker D, DiFigilo C, Lee I. A Clinical-Trial of Topical 10-Percent Trolamine Salicylate in Osteoarthritis. *Curr Ther Res Clin E*. 1994;55:584-597.
34. Rothacker DQ, Lee I, Littlejohn TW. Effectiveness of a single topical application of 10% trolamine salicylate cream in the symptomatic treatment of osteoarthritis. *J Clin Rheumatol*. 1998;4:6-12.
35. Sautner J, Andel I, Rintelen B, Leeb BF. Development of the M-SACRAH, a modified, shortened version of SACRAH (Score for the Assessment and Quantification of Chronic Rheumatoid Affections of the Hands). *Rheumatology (Oxford)*. 2004;43:1409-1413.

36. Sautner J, Andel I, Rintelen B, Leeb BF. A Comparison of the Modified Score for the Assessment of Chronic Rheumatoid Affections of the Hands and the Australian/Canadian Osteoarthritis Hand Index in Hand Osteoarthritis Patients. *Int J Rheumatol.* 2009;249096.
37. Saviola G, Abdi-Ali L, Campostrini L, Sacco S, Baiardi P, Manfredi M, et al. Clodronate and hydroxychloroquine in erosive osteoarthritis: a 24-month open randomized pilot study. *Mod Rheumatol.* 2012;22:256-263.
38. Saviola G, Abdi-Ali L, Povino MR, Campostrini L, Sacco S, Carbonare LD. Intramuscular clodronate in erosive osteoarthritis of the hand is effective on pain and reduces serum COMP: a randomized pilot trial-The ER.O.D.E. study (ERosive Osteoarthritis and Disodium-clodronate Evaluation). *Clin Rheumatol.* 2017;36:2343-2350.
39. Schnitzer T, Morton C, Coker S. Topical Capsaicin Therapy for Osteoarthritis Pain: Achieving a Maintenance Regimen. *Seminars in Arthritis Rheum.* 1994;23:34-40.
40. Shin K, Kim JW, Moon KW, Yang JA, Lee EY, Song YW, et al. The Efficacy of Diacerein in Hand Osteoarthritis: A Double-Blind, Randomized, Placebo-Controlled Study. *Clin Ther.* 2013;35:431-439.
41. Sofat N, Harrison A, Russell MD, Ayis S, Kiely PD, Baker EH, et al. The effect of pregabalin or duloxetine on arthritis pain: a clinical and mechanistic study in people with hand osteoarthritis. *J Pain Res.* 2017;10:2437-2449.
42. Spolidoro Paschoal Nde O, Natour J, Machado FS, de Oliveira HA, Furtado RN. Effectiveness of Triamcinolone Hexacetonide Intraarticular Injection in Interphalangeal Joints: A 12-week Randomized Controlled Trial in Patients with Hand Osteoarthritis. *J Rheumatol.* 2015;42:1869-1877.
43. Stamm TA, Machold KP, Smolen JS, Fischer S, Redlich K, Graninger W, et al. Joint protection and home hand exercises improve hand function in patients with hand osteoarthritis: A randomized controlled trial. *Arthrit Rheum.* 2002;47:44-49.
44. Stange-Rezende L, Stamm TA, Schiffert T, Sahinbegovic E, Gaiger A, Smolen J, et al. Clinical study on the effect of infrared radiation of a tiled stove on patients with hand osteoarthritis. *Scan J Rheum.* 2006;35:476-480.
45. Tubach F, Ravaud P, Martin-Mola E, Awada H, Bellamy N, Bombardier C, et al. Minimum clinically important improvement and patient acceptable symptom state in pain and function in rheumatoid arthritis, ankylosing spondylitis, chronic back pain, hand osteoarthritis, and hip and knee osteoarthritis: Results from a prospective multinational study. *Arthrit Care Res.* 2012;64:1699-1707.
46. van Velden D, Reuter H, Kidd M, Muller F. Non-allopathic adjuvant management of osteoarthritis by alkalisation of the diet. *Afr J Prm Health Care Fam Med.* 2015;7,Art. #780.
47. Watt FE, Kennedy DL, Carlisle KE, Freidin AJ, Szydlo RM, Honeyfield L, et al. Night-time immobilization of the distal interphalangeal joint reduces pain and extension deformity in hand osteoarthritis. *Rheumatology.* 2014;53:1142-1149.
48. Wenham CYJ, Hensor EMA, Grainger AJ, Hodgson R, Balamoody S, Dore CJ, et al. A randomized, double-blind, placebo-controlled trial of low-dose oral prednisolone for treating painful hand osteoarthritis. *Rheumatology (Oxford).* 2012;51:2286-2294.
49. Widrig R, Suter A, Saller R, Melzer J. Choosing between NSAID and arnica for topical treatment of hand osteoarthritis in a randomised, double-blind study. *Rheumatol Int.* 2007;27:585-591.
50. Wittoek R, Cruyssen BV, Maheu E, Verbruggen G. Cross-cultural adaptation of the Dutch version of the Functional Index for Hand Osteoarthritis (FIHOA) and a study on its construct validity. *Osteoarthritis and cartilage.* 2009;17:607-612.

Supplementary Table 1: Details of included studies

For Peer Review

Studies	Source Population, <b>No. Patients (% women),</b> Mean Age, Yrs	Definition of Hand OA and Inclusion criteria	Study Design (Outcome) Duration	Pain (VAS or NRS) (range)	PGA (VAS or NRS) (range)
Aitken, <i>et al.</i> 2018 (1)	Secondary care, <b>43 (77)</b> , 61	ACR criteria	RCT, cross over study (intervention = control) <sup>§</sup> , 12 weeks	VAS (0-100mm)	-
Baltzer, <i>et al.</i> 2016 (2)	Secondary care, <b>34 (94)</b> , 61	Bony nodes, symptoms and radiographic	Interventional study, 8 weeks	VAS (0-10cm)	-
Barthel, <i>et al.</i> 2010 (3)	Secondary care, <b>783 (80)</b> , 64	ACR criteria, KL $\geq$ 1, symptoms $\geq$ 1 yr	RCT (intervention > control) <sup>†</sup> , 8 weeks	VAS (0-100mm)	VAS (0-100mm)
Bjurehed, <i>et al.</i> 2017 (4)	Primary care, <b>49 (88)</b> , 69	Radiographic and symptoms, physician's diagnosis	Interventional study, 3 months	VAS (0-100mm)	-
Brosseau, <i>et al.</i> 2005 (5)	Secondary care, <b>88 (78)</b> , 65	ACR criteria, radiographic OA	RCT (intervention = control), 6 weeks	VAS (0-100mm)	-
Chevalier, <i>et al.</i> 2015 (6)	Secondary care, <b>85 (86)</b> , 63	ACR criteria, KL $\geq$ 2, VAS pain $\geq$ 40, $\geq$ 3 symptomatic joints > 3 months	RCT (intervention = control), 6 months	VAS (0-100mm)	VAS (0-100mm)
Dilek, <i>et al.</i> 2013 (7)	Secondary care, <b>56 (89)</b> , 59	ACR criteria	RCT (intervention > control), 3 weeks	VAS (0-10cm)	-
Dreiser, <i>et al.</i> 1993 (8)	Secondary care, <b>60 (85)</b> , 59	Radiographic OA	RCT (intervention > control), 2 weeks	VAS (0-100mm)	-
Fioravanti, <i>et al.</i> 2014 (9)	Primary care, <b>60 (87)</b> , 71	ACR criteria, symptomatic	RCT (intervention > control), 2 weeks, FU 12 months	VAS (0-100mm)	-
Gabay, <i>et al.</i> 2011 (10)	Secondary care, <b>162 (74)</b> , 63	ACR criteria, radiographic OA $\geq$ 2 joints $\geq$ 2 flares finger OA	RCT (intervention > control), 6 months	VAS (0-100mm)	-
Garfinkel, <i>et al.</i> 1994 (11)	Not specified, <b>25 (56)</b> , range 52-79	ACR criteria	RCT (intervention > control), 10 weeks	VAS	-
Grifka, <i>et al.</i> 2004 (12)	Secondary care, <b>594 (83)</b> , 62	ACR criteria, symptomatic > 3 months	RCT (intervention > control), 4 weeks	VAS (0-100mm)	VAS (0-100mm)
Gyarmati, <i>et al.</i> 2017 (13)	Secondary care, <b>47 (96)</b> , 64	ACR criteria, OA pain hands > 3 months	RCT (intervention 1 = intervention 2), 3 weeks	VAS (0-100mm)	VAS (0-100mm)
Hennig, <i>et al.</i> 2015 (14)	Secondary care, <b>80 (100)</b> , 61	ACR criteria, physician's diagnosis	RCT (intervention 1 > intervention 2), 3 months	NRS (0-10)	NRS (0-10)
Horvath, <i>et al.</i> 2011 (15)	Secondary care, <b>63 (81)</b> , 63	ACR criteria, radiographic OA, pain $\geq$ 3 months	RCT (intervention > control), 3 weeks	VAS (0-100mm)	VAS (0-100mm)
Kanat, <i>et al.</i> 2013 (16)	Not specified, <b>50 (100)</b> , 63	ACR criteria	RCT (intervention > control), 10 days	NRS (1-10)	-
Kasapoglu, <i>et al.</i> 2017	Secondary care,	Radiographic OA, KL >2, VAS $\geq$ 4/10	RCT (intervention 1 > intervention 2),	VAS (0-10cm)	-

(17)	55 (93), 60		1 month		
Keen, <i>et al.</i> 2010 (18)	Secondary care, 36 (86), 58	ACR criteria, radiographic OA	Interventional study, 4 weeks	VAS (0-10cm)	VAS (0-10cm)
Kjeken, <i>et al.</i> 2011 (19)	Secondary care, 70 (97), 61	ACR criteria	RCT (intervention = control), 3 months	VAS (0-100mm)	-
Kortekaas, <i>et al.</i> 2014 (20)	Secondary care, 25 (76), 60	ACR criteria	Observational, FU 3 months	VAS (0-100mm)	-
Kovács, <i>et al.</i> 2012 (21)	Secondary care, 45 (93), 59	ACR criteria, KL $\geq 2$ in $\geq 2$ joints, VAS pain $\geq 30$	RCT (intervention > control), 3 weeks	VAS (0-100mm)	-
Kvien, <i>et al.</i> 2008 (22)	Secondary care, 83 (93), 60	ACR criteria, KL $\geq 2$ , $\geq 1$ swollen/tender joint, VAS pain $\geq 30$	RCT (intervention > control), 42 days	VAS (0-100mm)	VAS (0-100mm)
Lee, <i>et al.</i> 2017 (23)	Secondary care, 196 (86), 58	ACR criteria, KL $\geq 2$	RCT (intervention = control), 24 weeks	VAS (0-100mm)	-
Moe, <i>et al.</i> 2010 (24)	Secondary care, 128 (91), 69	ACR criteria	Observational, cross sectional	VAS (0-100mm)	-
Moe <i>et al.</i> 2016 (25)	Secondary care, 391 (86), 61	ACR criteria	RCT (intervention > control), 1 yr	NRS (0-10)	-
Myrer, <i>et al.</i> 2011 (26)	Volunteers, 35 (77), 64	ACR criteria, FIHOA > 5	RCT (intervention > control), 4 weeks	VAS (0-100mm)	-
Neuprez, <i>et al.</i> 2015 (27)	Tertiary care, 203 (90), 69	ACR criteria	Observational, cross-sectional	VAS (0-100mm)	-
Osteras, <i>et al.</i> 2014 (28)	Population based, 130 (90), 66	ACR criteria	RCT (intervention > control), 12 weeks	NRS (0-10)	NRS (0-10)
Park, <i>et al.</i> 2016 (29)	Secondary care, 130 (90), 66	ACR criteria	RCT (intervention > control), 12 weeks	-	VAS (0-100mm)
Pastinen, <i>et al.</i> 1988 (30)	Secondary care, 29 (79), 58	Clinical/ radiographic finger OA	RCT (intervention > control), 14 weeks	VAS (0-10cm)	-
Poiraudeau, <i>et al.</i> 2001 (31)	Secondary care, 89 (91), 63	ACR criteria	Observational, FU 6 months	VAS (0-100mm)	-
Romero-Cerecero, <i>et al.</i> 2013 (32)	Not specified, 113 (95), 62	ACR criteria, radiographic OA $\geq 2$ IP joints, VAS $\geq 40$ , FIHOA $\geq 5$	RCT (intervention = control), 6 weeks	VAS (0-10cm)	-
Rothacker, <i>et al.</i> 1994 (33)	Not specified, 49 (84), 66	Physician diagnosed/radiographic OA, symptoms	RCT (intervention > control), FU 15-120 min (after cream)	NRS (1-5)	-
Rothacker, <i>et al.</i> 1998 (34)	Secondary care, 81 (74), 61	Physician diagnosed OA, symptoms	RCT (intervention > control), FU 30-120 min (after cream)	NRS (1-5)	-
Sautner, <i>et al.</i> 2004 (35)	Secondary care, 60 (73), 62	ACR criteria	Observational, cross-sectional	-	VAS (0-100mm)
Sautner, <i>et al.</i> 2009 (36)	Secondary care, 66 (77), 58	ACR criteria	Observational, cross-sectional	-	VAS (0-100mm)
Saviola, <i>et al.</i> 2012 (37)	Secondary care,	Radiographic erosive OA $\geq 2$ joints,	RCT (intervention 1 > intervention 2),	VAS (0-10cm)	-

	<b>38 (95)</b> , 61	VAS $\geq$ 40	1 and 2 yr		
Saviola, <i>et al.</i> 2017 (38)	Secondary care, <b>40 (93)</b> , 70	Radiographic erosive OA > 1 IP joints, VAS $\geq$ 4/10	RCT (intervention 1 > intervention 2), 6 months	VAS (0-10cm)	VAS (0-10cm)
Schnitzer, <i>et al.</i> 1994 (39)	Not specified, <b>59 (68)</b> , 68	Radiographic/physical OA findings	RCT (intervention > control), 9 weeks	VAS (0-100mm)	-
Shin, <i>et al.</i> 2013 (40)	Secondary care, <b>86 (97)</b> , 58	ACR criteria	RCT (intervention = control), 12 weeks	-	VAS (0-100mm)
Sofat, <i>et al.</i> 2017 (41)	Secondary care, <b>65 (80)</b> , 63	ACR criteria	RCT (intervention 1 > intervention 2 > control), 12 weeks	NRS (0-10)	-
Spolidoro Pashoal, <i>et al.</i> 2015 (42)	Secondary care, <b>60 (97)</b> , 61	ACR criteria	RCT (intervention 1 > intervention 2), 12 weeks	VAS (0-10cm)	-
Stamm, <i>et al.</i> 2002 (43)	Secondary care, <b>40 (88)</b> , 60	ACR criteria	RCT (intervention > control), 3 months	VAS (0-100mm)	-
Stange-Rezende, <i>et al.</i> 2006 (44)	Secondary care, <b>45 (93)</b> , 60	ACR criteria	RCT (intervention = control), 3 weeks	VAS (0-100mm)	-
Tubach, <i>et al.</i> 2012 (45)	Secondary care, <b>249 (88)</b> , 64	ACR criteria	Interventional, FU 4 weeks	NRS (0-10)	NRS (0-10)
Van Velden, <i>et al.</i> 2015 (46)	Primary care, <b>100 (not specified)</b> , 65	ACR criteria	RCT, cross over study (intervention > control), 56 days	VAS (0-10cm)	-
Watt, <i>et al.</i> 2014 (47)	Secondary care, <b>26 (88)</b> , 63	ACR criteria, NRS pain $\geq$ 2, radiographic deformity	CT (intervention > control), 3 months	NRS (0-10)	-
Wenham, <i>et al.</i> 2012 (48)	Not specified, <b>70 (81)</b> , 61	ACR criteria	RCT (intervention = control), 4 weeks	VAS (0-100mm)	-
Widrig, <i>et al.</i> 2007 (49)	Primary and secondary care, <b>204 (74)</b> , 64	ACR criteria, radiographic OA $\geq$ 2 joints, VAS $\geq$ 40, FIHOA $\geq$ 5	RCT (intervention = control), 3 weeks	VAS (0-100mm)	-
Wittoek, <i>et al.</i> 2009 (50)	Secondary care, <b>72 (89)</b> , 62	ACR criteria	Observational, cross-sectional	VAS (0-100mm)	-

- : not included; \* Intervention group performed better than control group, according to the primary outcome measure. <sup>§</sup> Intervention group did not perform better than control group, according to the primary outcome measure. OA: osteoarthritis; Yr(s): year(s); VAS: visual analogue score; NRS: numeric rating scale; PtGA: patient global assessment; ACR: American College of Rheumatology; RCT: randomized controlled trial; KL: Kellgren and Lawrence; IP: interphalangeal; FU: follow up; CT: clinical trial; FIHOA: Functional Index for Hand OA

Supplementary Table 2: Details of phrasing of question accompanying VAS or NRS pain

Reference	Scale	Explicite phrasing <sup>5</sup>	Time of recall	Other details
<i>RCT/Interventional studies</i>				
Aitken, <i>et al.</i> 2018 (1)	VAS (0-100mm)	Yes	1 week	
Baltzer, <i>et al.</i> 2016 (2)	VAS (0-10)	No	ND	
Barthel, <i>et al.</i> 2010 (3)	VAS (0-100mm)	No	24 hours	Dominant hand
Bjrehed, <i>et al.</i> 2017 (4)	VAS (0-100mm)	No	current	At rest
Brosseau, <i>et al.</i> 2005 (5)	VAS (0-100mm)	No	ND	Pain intensity
Chevalier, <i>et al.</i> 2015 (6)	VAS (0-100mm)	Yes	24 hours	Global pain
Dilek, <i>et al.</i> 2013 (7)	VAS (0-10 cm)	No	48 hours	Pain at rest and during daily activity, both hands and hands separately
Dreiser, <i>et al.</i> 1993 (8)	VAS (0-100mm)	No	ND	Overall spontaneous pain
Fioravanti, <i>et al.</i> 2014 (9)	VAS (0-100mm)	No	ND	
Gabay, <i>et al.</i> 2011 (10)	VAS (0-100mm)	No	ND	Global spontaneous hand pain
Garfinkel, <i>et al.</i> 1994 (11)	VAS	No	ND	Hand pain at rest and during activity
Grifka, <i>et al.</i> 2004 (12)	VAS (0-100mm)	Yes	24 hours	Pain intensity In target hand
Gyarmati, <i>et al.</i> 2017 (13)	VAS (0-100mm)	No	ND	At rest and on exertion
Hennig, <i>et al.</i> 2015 (14)	NRS (0-10)	No	ND	
Horváth, <i>et al.</i> 2011 (15)	VAS (0-100mm)	No	ND	Severity of pain at rest and upon exertion; in small hand joints of the hands
Kanat, <i>et al.</i> 2013 (16)	NRS (1-10)	No	ND	Hand pain at rest and on use
Kasapoglu, <i>et al.</i> 2017 (17)	VAS (0-10cm)	No	ND	
Keen, <i>et al.</i> 2010 (18)	VAS (0-10cm)	No	ND	Most painful joint, all joints of both hands
Kjeken, <i>et al.</i> 2011 (19)	VAS (0-100mm)	No	ND	
Kovács, <i>et al.</i> 2012 (21)	VAS (0-100mm)	No	ND	
Kvien, <i>et al.</i> 2008 (22)	VAS (0-100mm)	Yes	48 hours	Pain intensity
Lee, <i>et al.</i> 2017 (23)	VAS (0-100mm)	No	24 hours	
Moe, <i>et al.</i> 2016 (25)	NRS (0-10)	No	ND	
Myrer, <i>et al.</i> 2011 (26)	VAS (0-100mm)	Yes	1 week, current	Pain at rest, pain upon movement, current pain
Osteras, <i>et al.</i> 2014 (28)	NRS (0-10)	No	ND	
Pastinen, <i>et al.</i> 1988 (30)	VAS (0-10cm)	No	ND	Pain provoked by grip and pinch strength tests
Romero-Cerecero, <i>et al.</i> 2013 (32)	VAS (0-10cm)	No	ND	Pain intensity
Rothacker, <i>et al.</i> 1994 (33)	NRS (1-5)	No	Immediately	
Rothacker, <i>et al.</i> 1998 (34)	NRS (1-5)	No	ND	
Saviola, <i>et al.</i> 2012 (37)	VAS (0-10cm)	No	ND	
Saviola, <i>et al.</i> 2017 (38)	VAS (0-10cm)	No	ND	
Schnitzer, <i>et al.</i> 1994 (39)	VAS (0-100mm)	No	ND	Level of pain
Sofat, <i>et al.</i> 2017 (41)	NRS (0-10)	No	ND	

Spolidoro Pashoal, <i>et al.</i> 2015 (42)	VAS (0-10cm)	No	ND	Pain at rest, on movement
Stamm, <i>et al.</i> 2002 (43)	VAS (0-100mm)	No	ND	
Stange-Rezende, <i>et al.</i> 2006 (44)	VAS (0-100mm)	No	ND	General level of pain
Tubach, <i>et al.</i> 2012 (45)	NRS (0-10)	Yes	48hours	
Van Velden, <i>et al.</i> 2015 (46)	VAS (0-10)	No	ND	
Watt, <i>et al.</i> 2014 (47)	NRS (0-10)	No	1 week	Average pain, worst pain
Wenham, <i>et al.</i> 2012 (48)	VAS (0-100mm)	Yes	48 hours, 2 weeks	Average pain both hands, in the most painful joints, at 1st CMC
Widrig, <i>et al.</i> 2007 (49)	VAS (0-100mm)	Yes	24 hours	Finger level
<i>Observational studies</i>				
Kortekaas, <i>et al.</i> 2014 (20)	VAS (0-100mm)	No	ND	
Moe, <i>et al.</i> 2010 (24)	VAS (0-100mm)	No	ND	
Neuprez, <i>et al.</i> 2015 (27)	VAS (0-100mm)	No	ND	Global assessment of pain
Poiraudeau, <i>et al.</i> 2001 (31)	VAS (0-100mm)	No	ND	Pain intensity
Wittoek, <i>et al.</i> 2009 (50)	VAS (0-100mm)	No	1 week	Global pain, both hands

VAS: visual analogue scale; NRS: numeric rating scale; ND: not defined

<sup>§</sup> Explicit phrasing of scales in domain pain:

- *On this line, where would you rate your pain, using the last 7 days as a timeframe?* (1)
- *What is the global level of pain in your hands in the past 24 hours?* (6)
- *Indicate the most pain from your OA in the target hand over the previous 24hours?* (12)
- *How would you describe the intensity of your joint pain during the last 2 days?* (22)
- *How would you estimate your perception of average 'pain at rest' and average 'pain with movement' over the week prior to the assessment?* (26)
- *Circle the number that best describes the pain you felt due to your hand osteoarthritis during the last 48 hours?* (45)
- *Indicate the level of pain in the hands during the last 48 hours/ last 2 weeks?* (48)
- *Indicate the level of pain in the most painful joint during the last 48 hours?* (48)
- *Indicate the level of pain at the 1st CMC joint during the last 48 hours?* (48)
- *Indicate the most intense pain in the previous 24 hours in the worst affected finger?* (49)

Supplementary Table 3: Details of phrasing of question accompanying VAS or NRS PGA


Reference	Scale	Exact phrasing <sup>§</sup>	Time of recall	Other comments
<i>RCT/Interventional studies</i>				
Barthel, <i>et al.</i> 2010 (3)	VAS (0-100mm)	Yes	ND	Global assessment of disease activity
Chevalier, <i>et al.</i> 2015 (6)	VAS (0-100mm)	No	ND	
Griftka, <i>et al.</i> 2004 (12)	VAS (0-100mm)	No	ND	Global assessment of disease activity
Gyermati, <i>et al.</i> 2017 (13)	VAS (0-100mm)	No	ND	
Hennig, <i>et al.</i> 2015 (14)	NRS (0-10)	No	ND	Global assessment of disease activity
Horváth, <i>et al.</i> 2011 (15)	VAS (0-100mm)	No	ND	
Keen, <i>et al.</i> 2010 (18)	VAS (0-10 cm)	No	ND	
Kvien, <i>et al.</i> 2008 (22)	VAS (0-100mm)	Yes	48 hours	
Osteras, <i>et al.</i> 2014 (28)	NRS (0-10)	No	ND	Global assessment of disease activity and disease activity affecting activities in daily life
Park, <i>et al.</i> 2016 (29)	VAS (0-100mm)	No	ND	General health
Saviola, <i>et al.</i> 2017 (38)	VAS (0-10 cm)	No	ND	Global assessment of disease activity
Shin, <i>et al.</i> 2013 (40)	VAS (0-100mm)	No	ND	
<i>Observational studies</i>				
Sautner, <i>et al.</i> 2004 (35)	VAS (0-100mm)	No	ND	
Sautner, <i>et al.</i> 2009 (36)	VAS (0-100mm)	Yes	48 hours	
Tubach, <i>et al.</i> 2012 (45)	NRS (0-10)	Yes	48 hours	

VAS: visual analogue scale; NRS: numeric rating scale; ND: not defined


<sup>§</sup> Explicit phrasing of scales in domain PGA:

- Considering all the ways osteoarthritis of your hands affects you, please indicate with an 'X' through the horizontal line how well are you doing? (3)
- We ask you to evaluate the activity of your osteoarthritis over the last 2 days? When you take all symptoms into consideration, how will you evaluate your condition? (22)
- Please indicate how severe you are compromised by your hand osteoarthritis during the last 48 hours? (36)
- Considering all the ways your hand osteoarthritis has affected you during the last 48 hours, circle the number that best describes how you have been doing? (45)

FROM SLR VISSER ET AL. (UNTIL JANUARY 2014)



FROM SLR (FROM JANUARY 2014 – JANUARY 2018)



\*original SLR, all instruments for pain, PGA and function were included

## STATEMENT OF CONTRIBUTION

We declare that this manuscript presents substantial new information that is evaluable by peer review.

**Main findings:** This report includes the results of a recent systematic literature review on instruments (visual analogue and numeric rating scale) in the domains pain and patient global assessments in hand osteoarthritis (OA). Also in other domains, progress in validation of certain instruments has been made. Michigan Hand Outcomes Questionnaire had advantages above other pain/function questionnaires. Hand Mobility in Scleroderma was valid, although responsiveness was questioned.

**What is novel:** This report gives an overview of new evidence contributing to instrument validation in certain domains in hand OA. The discussion and proposed research agenda of OMERACT 2018 is reported.

**How it advances published research to date:** A good overview is provided of where remaining gaps exist for further validation of several instruments before final core instrument set selection in hand OA. The discussions held at OMERACT 2018 serve as a basis for the future research agenda.

**Status regarding prior publication/submission elsewhere:** This work was not previously published or submitted elsewhere.